[1] Cardoso CRL, Salles GC, Leite NC, Salles GF: Prognostic impact of carotid intima-media thickness and carotid plaques on the development of micro- and macrovascular complications in individuals with type 2 diabetes: the Rio de Janeiro type 2 diabetes cohort study. Cardiovasc Diabetol 2019, 18(1):2.
[2] Centurion OA: Carotid Intima-Media Thickness as a Cardiovascular Risk Factor and Imaging Pathway of Atherosclerosis. Crit Pathw Cardiol 2016, 15(4):152-160.
[3] Stein JH, Korcarz CE, Hurst RT, Lonn E, Kendall CB, Mohler ER, Najjar SS, Rembold CM, Post WS: Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: a consensus statement from the American Society of Echocardiography Carotid Intima-Media Thickness Task Force. Endorsed by the Society for Vascular Medicine. J Am Soc Echocardiogr 2008, 21(2):93-111; quiz 189-190.
[4] Van Montfort R, Slingsby C, Vierling E: Structure and function of the small heat shock protein/alpha-crystallin family of molecular chaperones. Adv Protein Chem 2001, 59:105-156.
[5] Beck FX, Neuhofer W, Muller E: Molecular chaperones in the kidney: distribution, putative roles, and regulation. Am J Physiol Renal Physiol 2000, 279(2):F203-215.
[6] Ranford JC, Henderson B: Chaperonins in disease: mechanisms, models, and treatments. Mol Pathol 2002, 55(4):209-213.
[7] Batulan Z, Pulakazhi Venu VK, Li Y, Koumbadinga G, Alvarez-Olmedo DG, Shi C, O'Brien ER: Extracellular Release and Signaling by Heat Shock Protein 27: Role in Modifying Vascular Inflammation. Front Immunol 2016, 7:285.
[8] Martin-Ventura JL, Duran MC, Blanco-Colio LM, Meilhac O, Leclercq A, Michel JB, Jensen ON, Hernandez-Merida S, Tunon J, Vivanco F et al: Identification by a differential proteomic approach of heat shock protein 27 as a potential marker of atherosclerosis. Circulation 2004, 110(15):2216-2219.
[9] Seibert TA, Hibbert B, Chen YX, Rayner K, Simard T, Hu T, Cuerrier CM, Zhao X, de Belleroche J, Chow BJ et al: Serum heat shock protein 27 levels represent a potential therapeutic target for atherosclerosis: observations from a human cohort and treatment of female mice. J Am Coll Cardiol 2013, 62(16):1446-1454.
[10] Lepedda AJ, Cigliano A, Cherchi GM, Spirito R, Maggioni M, Carta F, Turrini F, Edelstein C, Scanu AM, Formato M: A proteomic approach to differentiate histologically classified stable and unstable plaques from human carotid arteries. Atherosclerosis 2009, 203(1):112-118.
[11] Lu B, Yang Y, Yang Z, Feng X, Wang X, Zhang Z, Hu R: Insulin resistance in Chinese patients with type 2 diabetes is associated with C-reactive protein independent of abdominal obesity. Cardiovasc Diabetol 2010, 9:92.
[12] Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28(7):412-419.
[13] K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002, 39(2 Suppl 1):S1-266.
[14] Jakhotia S, Sivaprasad M, Shalini T, Reddy PY, Viswanath K, Jakhotia K, Sahay R, Sahay M, Reddy GB: Circulating levels of Hsp27 in microvascular complications of diabetes: Prospects as a biomarker of diabetic nephropathy. J Diabetes Complications 2018, 32(2):221-225.
[15] Arrigo AP, Virot S, Chaufour S, Firdaus W, Kretz-Remy C, Diaz-Latoud C: Hsp27 consolidates intracellular redox homeostasis by upholding glutathione in its reduced form and by decreasing iron intracellular levels. Antioxid Redox Signal 2005, 7(3-4):414-422.
[16] Rayner K, Chen YX, McNulty M, Simard T, Zhao X, Wells DJ, de Belleroche J, O'Brien ER: Extracellular release of the atheroprotective heat shock protein 27 is mediated by estrogen and competitively inhibits acLDL binding to scavenger receptor-A. Circ Res 2008, 103(2):133-141.
[17] Pulakazhi Venu VK, Adijiang A, Seibert T, Chen YX, Shi C, Batulan Z, O'Brien ER: Heat shock protein 27-derived atheroprotection involves reverse cholesterol transport that is dependent on GM-CSF to maintain ABCA1 and ABCG1 expression in ApoE(-/-) mice. Faseb j 2017, 31(6):2364-2379.
[18] Cuerrier CM, Chen YX, Tremblay D, Rayner K, McNulty M, Zhao X, Kennedy CR, de BelleRoche J, Pelling AE, O'Brien ER: Chronic over-expression of heat shock protein 27 attenuates atherogenesis and enhances plaque remodeling: a combined histological and mechanical assessment of aortic lesions. PLoS One 2013, 8(2):e55867.
[19] De AK, Kodys KM, Yeh BS, Miller-Graziano C: Exaggerated human monocyte IL-10 concomitant to minimal TNF-alpha induction by heat-shock protein 27 (Hsp27) suggests Hsp27 is primarily an antiinflammatory stimulus. J Immunol 2000, 165(7):3951-3958.
[20] Osterloh A, Breloer M: Heat shock proteins: linking danger and pathogen recognition. Med Microbiol Immunol 2008, 197(1):1-8.
[21] Najemnikova E, Rodgers CD, Locke M: Altered heat stress response following streptozotocin-induced diabetes. Cell Stress Chaperones 2007, 12(4):342-352.
[22] Shi C, Ulke-Lemee A, Deng J, Batulan Z, O'Brien ER: Characterization of heat shock protein 27 in extracellular vesicles: a potential anti-inflammatory therapy. Faseb j 2019, 33(2):1617-1630.
[23] Park HK, Park EC, Bae SW, Park MY, Kim SW, Yoo HS, Tudev M, Ko YH, Choi YH, Kim S et al: Expression of heat shock protein 27 in human atherosclerotic plaques and increased plasma level of heat shock protein 27 in patients with acute coronary syndrome. Circulation 2006, 114(9):886-893.
[24] Zhang HL, Jia KY, Sun D, Yang M: Protective effect of HSP27 in atherosclerosis and coronary heart disease by inhibiting reactive oxygen species. J Cell Biochem 2019, 120(3):2859-2868.
[25] Jin C, Phillips VL, Williams MJ, van Rij AM, Jones GT: Plasma heat shock protein 27 is associated with coronary artery disease, abdominal aortic aneurysm and peripheral artery disease. Springerplus 2014, 3:635.
[26] Martin-Ventura JL, Nicolas V, Houard X, Blanco-Colio LM, Leclercq A, Egido J, Vranckx R, Michel JB, Meilhac O: Biological significance of decreased HSP27 in human atherosclerosis. Arterioscler Thromb Vasc Biol 2006, 26(6):1337-1343.
[27] Lamfers ML, Grimbergen JM, Aalders MC, Havenga MJ, de Vries MR, Huisman LG, van Hinsbergh VW, Quax PH: Gene transfer of the urokinase-type plasminogen activator receptor-targeted matrix metalloproteinase inhibitor TIMP-1.ATF suppresses neointima formation more efficiently than tissue inhibitor of metalloproteinase-1. Circ Res 2002, 91(10):945-952.
[28] Choi SH, Lee HJ, Jin YB, Jang J, Kang GY, Lee M, Kim CH, Kim J, Yoon SS, Lee YS et al: MMP9 processing of HSPB1 regulates tumor progression. PLoS One 2014, 9(1):e85509.